To Compare the effects of Polyherbal Unani formulation with a standard control in the Management of Migraine without Aura

A Clinical Study on Migraine without Aura (Shaqeeqa) and its Management with Polyherbal Formulation- A Randomized Standard Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075060

Enrollment

Registered

2024-10-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G430- Migraine without aura

Interventions

Intervention1: Extract of Unani Polyherbal formulation- Ustukhuddus (Lavandula stoechas)100mg, Kishneez khushk (Coriandrum sativum)50mg, Filfil siyah (Piper nigrum)50mg, Tukhm-e-kahu (Lactuca sativa)1

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient willing to participate in the study and sign the informed consent form. 2.Patients between the age of 18 and 65 years of either sex. 3.Diagnosed cases of migraine based on ICHD-3 criteria.

Exclusion criteria

Exclusion criteria: 1.Patients of psychotic and neurotic disorder. 2.Patients taking Anti-migraine, Anti-epileptic, Anti- Psychotic, Anti-Depressant, Sedative and Hypnotic medications. 3.Patients with refractive errors. 4.Patients suffering from eye disease, otitis media, sinusitis, pharyngitis, gingivitis,rhinitis, and tonsillitis. 5.Pregnant and lactating women. 6.Renal & hepatic insufficiency and malignancy. 7.Diagnosed cases of Malignant Hypertension and Diabetes mellitus. 8.Patients with Bradycardia or Hypotension. 9.Diagnosed cases of obstructive pulmonary disease like COPD or Asthma. 10.Patients with neck muscle and cranial bones pain.

Design outcomes

Primary

Measure	Time frame
1.To assess the safety and efficacy of the proposed Unani Polyherbal Formulation on scientific parameters. 2.To compare the results of Polyherbal Unani Formulation with the standard control in the treatment of Migraine in respect of safety and efficacy.Timepoint: 1.To evaluate efficacy: a. Assessment of subjective parameters at base line, 10th, 20th, 30th, and 42nd Day. b. Assessment of Migraine disability at baseline and after 6 weeks. 2.To evaluate safety: Haemogram, LFT, KFT at base line, 10th day and after 6 weeks.	—

Measure

Time frame

1.To assess the safety and efficacy of the proposed Unani Polyherbal Formulation on scientific parameters. 2.To compare the results of Polyherbal Unani Formulation with the standard control in the treatment of Migraine in respect of safety and efficacy.Timepoint: 1.To evaluate efficacy: a. Assessment of subjective parameters at base line, 10th, 20th, 30th, and 42nd Day. b. Assessment of Migraine disability at baseline and after 6 weeks. 2.To evaluate safety: Haemogram, LFT, KFT at base line, 10th day and after 6 weeks.

—

Secondary

Measure	Time frame
To evaluate the effect of Unani Polyherbal Formulation on quality of life of the patient (QOL).Timepoint: Assessment of Quality of life of patient at baseline and after 6 weeks.	—

Countries

India

Contacts

Public ContactShaziya Siddiqui Niyaz Ahmed

Ayurvedic and Unani Tibbia College and Hospital

drkhannaseem.akhtarkhan@gmail.com9810815997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026